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Summary
Background Highly effective direct-acting antiviral drugs provide the opportunity to eliminate hepatitis C virus (HCV) 
infection, but established pathways can be ineffective. We aimed to examine whether a community pharmacy care 
pathway increased treatment uptake, treatment completion, and cure rates for people receiving opioid substitution 
therapy, compared with conventional care.
Methods This cluster-randomised trial was done in Scottish community pharmacies. Before participants were 
recruited, pharmacies were randomly assigned (1:1) to refer patients with evidence of HCV antibodies to 
conventional care or offered them care in the pharmacy (pharmacist-led care). Pharmacies were stratified by 
location. All pharmacies were trained to offer dried blood spot testing. All eligible participants had received opioid 
substitution therapy for approximately 3 months, and those eligible to receive treatment in the pharmacist-led care 
pathway were HCV PCR positive, were infected with HCV genotype 1 or 3, and were willing to have a pharmacist 
supervise their antiviral drug administration. Neither pharmacists nor patients were masked to treatment allocation. 
In both groups, assessment blood samples were taken, infection with HCV was confirmed, and daily oral ledipasvir–
sofosbuvir (90 mg ledipasivir plus 400 mg sofosbuvir) for 8 weeks for genotype 1 or daily oral sofosbuvir (400 mg) 
plus oral daclatasvir (60 mg) for 12 weeks for genotype 3 was prescribed by a nurse (conventional care group) or 
pharmacist (pharmacist-led care group). In the conventional care group, the patient received care at a treatment 
centre. Once prescribed, medication in both groups was delivered as daily modified directly observed therapy 
alongside opioid substitution therapy in the participants’ pharmacy where treatment was observed on 6 days per 
week. The primary outcome was the number of patients with sustained virological response 12 weeks after 
completion of treatment (SVR12) as a proportion of the number of people receiving opioid substitution therapy at 
participating pharmacies. Participants were monitored at each visit for nausea and fatigue; other adverse events 
were recorded as free text. Secondary outcomes compared key points on treatment pathway between the two groups. 
These key points were the proportion of patients having dry blood spot testing, the proportion of patients initiating 
HCV treatment, the proportion of patients completing the 8 or 12 week HCV course of treatment, and the proportion 
of patients with sustained virological response at 12 months. This study is registered with ClinicalTrials.gov, 
NCT02706223.
Findings 56 pharmacies were randomly assigned (28 to each group; one pharmacy withdrew from the conventional 
care group). The 55 participating pharmacies included 2718 patients receiving opioid substitution therapy (1365 in the 
pharmacist-led care group and 1353 in the conventional care group). More patients met the primary endpoint of 
SVR12 in the pharmacist-led care group (98 [7%] of 1365) than in the conventional care group (43 [3%] of 1353; odds 
ratio 2∙375, 95% CI 1∙555–3∙628, p<0∙0001). More users of opioid substitution therapy in the pharmacist-led care 
group versus the conventional care group agreed to dry blood spot testing (245 [18%] of 1365 vs 145 [11%] of 1353, 
2∙292, 0∙968–5∙427, p=0∙059); initiated treatment (112 [8%] of 1365 vs 61 [4%] of 1353, 1∙889, 1∙276–2∙789, p=0∙0015) 
and completed treatment (108 [8%] of 1365 vs 58 [4%] of 1353, 1∙928, 1∙321–2∙813, p=0∙0007). The data for sustained 
virological response at 12 months are not reported in this study: patients remain in follow-up for this outcome. No 
serious adverse events were recorded.
Interpretation Using pharmacists to deliver an HCV care pathway made testing and treatment more accessible 
for patients, improved engagement, and maintained high treatment success rates. The use of this pathway could be a 
key part of an integrated and effective approach to HCV elimination at a community level.
Funding Partnership between the Scottish Government, Gilead Sciences, and Bristol-Myers Squib.
Copyright © 2020 Elsevier Ltd. All rights reserved.






















Hepatitis C virus (HCV) is a blood-borne infection that 
causes liver disease. The worldwide burden of HCV has 
been estimated as 71∙1 million infections (95% CI 
62∙5–79∙4 million).1 In high-income countries, people 
who inject drugs are the group most commonly infected 
with HCV and approximately 60% (10 million people) of 
the global population of people who inject drugs have an 
HCV infection.2 It has been estimated that 50% of HCV 
infections in western Europe are caused by injection drug 
use.3 In current testing and treatment pathways within the 
UK, only a small proportion of patients who had a positive 
HCV test had evidence of ever receiving treatment 
(11∙9%), and even fewer had a sustained virological 
response (5∙9%).4
The conventional care pathway in the UK recommends 
that patients with a history of intravenous drug use, or 
who are prescribed opioid substitution therapy, should 
be offered HCV testing annually. Testing might be 
available from their general practitioner, drug workers, 
drug agencies, social workers, community pharmacies, 
and needle exchanges. Once diagnosed, patients can be 
referred to established treatment pathways, usually based 
around hepatology or infectious disease teams in 
secondary care.5 The inefficiency of established treatment 
pathways, with many patients lost from care, leads to 
increased preventable deaths from hepatitis C and viral 
transmission among people who inject drugs.6
Various reasons might explain the low rates of HCV 
testing, treatment uptake, and treatment completion. At 
the patient level, people who inject drugs might 
encounter several barriers that prevent them from 
accessing care, including stigma and discrimination, 
issues with the organisation of care, and the treatment 
policies of providers or payers.7 Low levels of health 
literacy might also limit understanding of their health, 
illness, and treatments, and people who inject drugs 
might find it difficult to consistently attend medical 
clinics.8,9 Simplifying care pathways to enable treatment 
initiation, clinical monitoring, and close treatment 
supervision in a familiar and convenient setting might 
be effective in overcoming these barriers.8 Offering 
hepatitis C care in primary care and community settings 
might increase uptake of treatment and maintain high 
rates of cure.6
In the UK, people who have injected drugs and are 
taking opioid substitution therapy receive treatment 
regularly from their local community pharmacy.10 
Community pharmacists are contractors to the UK 
National Health Service (NHS), as are general 
Research in context
Evidence before this study
Direct-acting antiviral drugs have a higher cure rate for 
hepatitis C virus (HCV) infection than previous medication 
regimens containing pegylated interferon alpha and ribavirin, 
and a lower treatment burden and monitoring requirement. 
Consequently, direct-acting antiviral drugs have replaced these 
older drugs in current practice and are advocated by WHO as a 
key tool in the elimination of HCV by 2030. Guidance on the 
prevention, care, and treatment of people with HCV 
recommends task-shifting to optimise available human 
resources and decentralisation of care to places where people 
with HCV infection already visit, so that the scale and reach of 
provision can be increased to achieve elimination. Direct-acting 
antiviral drugs could be delivered in the community by affiliated 
care professionals, including pharmacists. Databases (Cinahl; 
Embase; Medline; PsycINFO; PubMed) were searched between 
Jan 1, 2013, and Dec 31, 2017, for studies published in English of 
treatment with direct-acting antiviral drugs in non-specialist 
settings to achieve a sustained virological response. Relevant 
studies were identified, including those containing a 
comparison between a community and specialist services 
where available. A narrative synthesis and linked meta-analysis 
were done on suitable studies with a strength of evidence 
assessment. We did a systematic review and meta-analysis of 
community-based treatment pathways and identified 
17 studies showing that locally delivered care for patients with 
HCV is feasible and can facilitate increased uptake of treatment. 
Such community-based pathways might be able to show 
similar cure rates to those achieved by specialist clinics in 
secondary care. However, stronger study designs comparing 
community pathways with specialist care are needed to give 
more certainty about the effect size seen in current studies. 
Added value of this study
This cluster-randomised controlled study shows that 
community pharmacists are more likely to recruit patients 
prescribed opioid substitution therapy to an HCV care pathway 
than standard care, and that such patients are more likely to 
engage with treatment when the entire process of diagnosis 
and treatment is offered in the pharmacy. There was no 
evidence of disadvantageous effects, such as lower treatment 
completion or success rates.
Implications of all the available evidence
Transferring the primary responsibility for HCV diagnosis and 
treatment of patients prescribed opioid substitution therapy to 
community pharmacies, with guidance available from specialist 
teams, is likely to increase HCV treatment uptake and cure 
rates. This intervention could have an important role in a 
system-wide strategy aimed at eradicating HCV. Such services 
are in line with the WHO guidance for decentralisation of 
service delivery to primary care-based sites and of task-sharing. 
Close collaboration between specialist teams and community 
pharmacists offers an effective option for addressing HCV in 
this patient group and supports efforts aimed at HCV 
















practitioners and optom etrists, and provide services 
according to financial arrangements. Patients visit 
pharmacies much more often than secondary care sites, 
and pharmacies are often located nearer to areas of 
socioeconomic disadvantage, have longer opening hours, 
and can be accessed without an appointment. Pharmacy 
staff can be trained to offer dry blood spot testing to 
screen for HCV infection. In conventional care, after a 
positive HCV antibody test, patients are referred to a 
secondary care-based team; however, the opportunity to 
provide all diagnostic and treatment prescription services 
from pharmacies might represent a much more 
convenient and non-threatening route to HCV treatment 
for people who inject drugs and are taking opioid 
substitution therapy. Moreover, at the pharmacist level, 
having primary responsibility for HCV testing and 
treatment, and being able to offer potential patients with 
HCV a more convenient and acceptable treatment 
pathway, could enhance pharma cists’ motivation and 
effort to recruit patients to the pathway.
WHO has set targets to eliminate HCV as a public 
health threat by 2030.11 Creating the complex public health 
interventions necessary to eliminate HCV requires well 
designed cross-disciplinary programmes to be put in place 
to increase screening, testing, and diagnosis.12 Strategies 
advocated to increase linkage to care include integration 
with other services, decentralisation of primary care 
providers, and task-shifting to non-specialists.6
We aimed to evaluate whether a pharmacist-led care 
pathway compared with conventional care could increase 
HCV testing, treatment uptake and completion, and cure 
rates for the population of opioid substitution therapy 
recipients who are infected with HCV.
Methods
Study design and participants
This cluster-randomised controlled trial compared 
different HCV care pathways for patients receiving 
opioid substitution therapy in 55 community pharmacies 
in Scotland, overseen by three health boards. Ethics 
approval was granted by East of Scotland Research Ethics 
Committee 2 (15/ES/0086); sponsor, research and 
development, and Caldicott approvals were granted by 
University of Dundee, NHS Tayside, NHS Grampian, 
and NHS Greater Glasgow and Clyde. The protocol has 
been published elsewhere.13
Eligible pharmacies were community-based, were 
trained to offer dry blood spot testing for HCV by trained 
pharmacy staff, and had approximately 30 patients 
attending to receive opioid substitution therapy to ensure 
adequate recruitment to the trial. Within those 
pharmacies, all patients taking opioid substitution 
therapy were included in the trial, because they were the 
population at risk of HCV infection. Not all of the patients 
accepted testing.
Patients eligible to receive treatment in the pharmacist-
led care pathway were HCV PCR positive, were infected 
with HCV genotype 1 or 3, were using opioid substitution 
therapy, had attended the pharmacy for approximately 
3 months, and were willing to have a pharmacist 
supervise their antiviral drug administration. Patients 
were ineligible for receiving treatment in the context of 
this study if they had a HCV genotype other than 1 or 3, 
had a risk of cirrhosis (fibrosis-4 [FIB-4] score >3·25), 
had evidence of current or previous decompensated liver 
disease, had HIV infection, tested HBsAg positive with 
detectable hepatitis B virus (HBV) DNA, behaved 
aggressively or violently towards pharmacy staff, were 
pregnant, or were not able to provide informed consent. 
There were no age restrictions on study eligibility. Pan-
genotypic medicines were not available at the time of this 
study. All participants gave written informed consent.
Randomisation and masking
The unit of randomisation was eligible pharmacies. 
Before the start of recruitment, pharmacies were 
randomly assigned 1:1 to provide conventional care 
(group 1) or pharmacist-led care (group 2) using www.
randomization.com (by SKI) to generate randomly 
permuted blocks. SKI generated the sequence and 
allocated pharmacies to the conventional care group or 
the pharmacist-led care group. Participants were enrolled 
by the pharmacists in each pharmacy. Neither pharmacists 
nor patients were masked to treatment allocation, because 
knowledge of the intervention provided was necessary to 
enter the pathway—ie, undergoing HCV testing and 
initiating HCV treatment. Pharmacies were stratified by 
location so that each Scottish Health Board had equivalent 
numbers of treatment and control pharmacies.
Procedures
Before initiation of the study, good clinical practice 
training was provided to all participating pharmacy staff. 
In addition, training was provided on testing for 
bloodborne viruses, the interpretation of laboratory test 
results, FIB-4 score calculation to assess risk of cirrhosis, 
and the pathophysiology and treatment of HCV.14
Conventional care in the comparator group was 
provided by a highly developed multidisciplinary service 
from community treatment centres. During the study, 
pharmacists in the conventional care pathway oppor-
tunistically discussed HCV infection with patients taking 
opioid substitution therapy who attended the community 
pharmacy. Patients with unknown HCV status or 
previous negative results could be offered testing using a 
dry blood spot test in the pharmacy. Dry blood spot tests 
were sent to the local laboratory where they were analysed 
for HCV, HBV, and HIV infection. If PCR was required, 
this test was done at the regional laboratory. Results were 
usually communicated directly to the pharmacist within 
7 days. Patients who were recently or previously identified 
as having HCV were provided with an information leaflet 
explaining that their pharmacy was participating in a 
















having their data collected. Patients who were tested for 
HCV during the trial had a post-test discussion with the 
pharmacist using a standard infographic (appendix p 1) 
and were offered referral to a treatment centre. When the 
patient attended an appointment at a treatment centre, a 
member of the specialist hepatitis team assessed the 
patient for treatment for HCV as per standard of care. 
Assessment comprised medical history, concurrent 
medication, a full blood count, urea and electrolytes, liver 
function testing, and viral parameters (HCV genotype and 
viral load). Prescriptions for direct-acting antiviral 
treatment were provided by a nurse prescriber and 
dispensed at the participant’s community pharmacy.
Similarly to the conventional pathway, in the pharmacist-
led care pathway, pharmacists opportunistically discussed 
HCV infection with patients taking opioid substitution 
therapy who attended the pharmacy, and offered dry blood 
spot testing and communicated the possibility of receiving 
direct-acting antiviral treatment in the pharmacy 
to patients who tested positive for HCV (including patients 
who tested positively on a previous occasion, but who had 
not had treatment). People who identified as being HCV 
antibody-positive provided informed consent to receive 
their treatment from the pharmacist rather than 
conventional care, and for their data to be collected. In the 
pharmacist-led care pathway, the pharmacist assessed the 
participant for treatment, solely within the pharmacy. The 
pharmacist completed a pretreatment checklist of medical 
comorbidities, took a medicines history, and identified 
factors—such as history of non-attendance or treatment 
instability—that were likely to impinge on treatment 
compliance. A phlebotomist or nurse visited the pharmacy 
for assessment blood tests and the pharmacist determined 
suitability for treatment. When there were no contra-
indications to therapy, the patient commenced treatment. 
In patients with contraindications or about whom there 
were queries about suitability, the pharmacist contacted 
the specialist hepatitis team for advice. Potential partici-
pants with a FIB-4 score of more than 3·25 (and at risk of 
having cirrhosis) were referred to a hospital consultant. In 
Scotland, prescribing of direct-acting antiviral drugs is not 
limited to specialists but can be done by general 
practitioners, nurses, and pharmacists, as well as being 
made available by protocolised prescribing through 
patient group directions. Prescriptions for treatment in 
the pharmacist-led care pathway were provided by a 
pharmacist prescriber or through use of a patient group 
direction.15
The direct-acting antiviral treatment provided in both 
pathways was daily administration of oral ledipasvir–
sofosbuvir for 8 weeks for patients with genotype 1 
infections, and oral sofosbuvir plus oral daclatasvir for 
12 weeks for patients with genotype 3 infections. 
Ledipasvir–sofosbuvir (90 mg ledipasvir plus 400 mg 
sofosbuvir; Gilead Sciences, Foster City, CA, USA), 
sofosbuvir 400 mg (Gilead Sciences, Foster City, CA, USA), 
and daclatasvir 60 mg (Bristol-Myers Squibb, Princeton, 
NJ, USA) were provided free of charge through investigator 
sponsored research grants. The direct-acting antiviral 
treatment was administered concurrently with supervised 
opioid substitution therapy by the participant’s pharmacist, 
who observed con sumption (modified directly observed 
therapy). In both study groups, medications were usually 
carried away to be self-administered on Sundays when the 
pharmacy was closed. For doses that patients self-
administered, the pharmacist and patient made a brief if–
then action plan (an imple mentation intention) and coping 
plan (to overcome anticipated barriers).16
In both groups, daily monitoring was done at the 
pharmacy (excluding Sundays), including recording of 
any side-effects or adverse events. Participants were 
monitored at each visit for nausea and fatigue; other 
adverse events were recorded as free text. Participants 
who did not attend the pharmacy for 7 consecutive days 
had treatment discontinued and were deemed to have 
left the study. Fidelity of the intervention in both groups 
was promoted through standardised training and 
concurrent support from the study coordinators, who 
gave advice on implementation of the study protocol. 
Any breaches of protocol were reported to the sponsor. A 
comparison of treatment pathways between the two 
groups is shown in figure 1. An estimate of HCV 
prevalence from national surveillance data and within-
study testing was used in an exploratory analysis to 
describe the numbers of participants who might have 
HCV infection.17
Outcomes
The primary outcome of the study was the proportion 
of patients with sustained virological response 12 weeks 
after completion of treatment (SVR12) and was analysed 
in the intention-to-treat population.
Secondary outcomes were analysed in the intention-
to-treat population or per-protocol population, depen-
ding on the stage of the care cascade.18 These key points 
were the proportion of patients having dry blood spot 
testing, the proportion of patients initiating HCV 
treatment, the proportion of patients completing the 8 or 
12 week HCV course of treatment, and the proportion of 
patients with sustained virological response at 
12 months (to assess potential reinfection).
Statistical analysis
Sample size calculations assumed that approximately 
3% of HCV-positive patients on opioid substitution 
therapy enter HCV therapy per year via conventional 
pathways, with 2·5% of the total eligible population 
reaching a sustained virological response per annum. We 
estimated that the new pathway would increase the 
proportion of patients with sustained virological response 
to 15%, and on that basis, we calculated that a sample of 
141 patients in each group (total 282 patients) would be 
needed for 90% power (α=0·05). The clustered design 
requires inflation to account for intracluster correlation, 
















so if the average number of HCV-positive patients per 
pharmacy is 12, the inflation factor for sizes of cluster, 
assuming an intracluster correlation of 0·05, is 1·55. We 
therefore aimed to recruit 437 patients across both groups. 
The analysis was verified by an independent statistician.
The primary outcome of SVR12 was assessed as a 
binary outcome for patients and used logistic regression 
modelling in Stata MP. The primary analysis was done at 
the individual level in the intention-to-treat population, 
which included the number of patients on opioid 
substitution therapy in each treatment group, because 
this represents the population at risk of infection. 
All patients with missing SVR12 results were assumed to 
be treatment failures, therefore there were no missing 
data in the primary outcome. To account for the use of 
clustered randomisation, we used a mixed-effects logistic 
regression model with a parameter for study group, a 
random parameter to account for within-cluster 
correlation, and stratified by hub (Scottish Health Board). 
A sensitivity analysis was done assuming missing data 
represented treatment success, based on documentation 
of completion of treatment.19 Regression modelling was 
preplanned in the statistical analysis for type of therapy 
(ledipasvir–sofosbuvir, daclastavir plus sofosbuvir) and 
genotype (genotype 1, genotype 3), as well as hub data on 
the time between testing and initiating treatment. 
p values of less than 0·05 were assumed to be significant.
Secondary outcomes were also assessed as binary 
outcomes using the same procedure, initially in the 
intention-to-treat population, then as per protocol 
analysis of eligible patients at each stage.
We did a post-hoc analysis to investigate differences 
in attrition rates at individual steps between the 
two pathways, to explore any differences in patients’ 
behaviours once they had reached that stage. Cure rates 
were also calculated for the notional population at risk of 
infection and for the population diagnosed with HCV 
infection. The diagnosed population cure rate was the 
number of patients with SVR12 as a proportion of 
diagnosed patients. The notional population cure rate 
was the number of patients with SVR12 as a proportion 
of patients estimated to have an HCV infection. This 
study is registered with ClinicalTrials.gov, NCT02706223.
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
the data in the study and the corresponding author had 
final responsibility for the decision to submit for 
publication.
Results
Between Dec 9, 2016, and May 31, 2018, 2718 opioid 
substitution therapy recipients attended the 55 pharmacies 
that were randomly assigned to one of the two care 
pathways (28 pharmacies in the pharmacist-led care 
pathway group, 27 in the conventional care pathway 
group; figure 2).
Pharmacy and patient characteristics were similar 
between the two groups (tables 1, 2). Detailed infor-
mation is only available for patients who consented to 
Figure 1: Comparison of patient and pharmacist behaviours in the conventional care and pharmacist-led care pathways
HCV=hepatitis C virus. SVR=sustained virological response. *This stage in the pharmacist-led care pathway follows “Agree and take test” and leads to 
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have data collected when they elected to receive therapy. 
Of the 356 participants who had HCV infection and 
consented to take part in the study (137 in the 
conventional care pathway group, 219 in the pharmacist-
led care pathway group), 197 (55%) completed further 
blood tests and 185 (52%) completed assessments to 
define FIB-4 score and HCV genotype (figure 2). The 
2362 patients receiving opioid substitution therapy who 
did not commence treatment as part of this study were 
HCV-negative, had been previously treated, or declined 
testing. Through access to region-wide prescribing data, 
to the best of our knowledge, no eligible patients were 
treated outside the study.
Data on the number of patients at each site who were 
recruited, who were tested, who initiated and completed 
treatment, and who achieved SVR12 are shown in the 
appendix (p 2). 98 (7%) of 1365 participants in the 
pharmacist-led treatment group had SVR12 compared 
with 43 (3%) of 1353 participants in the conventional care 
group (odds ratio [OR] 2∙375, 95% CI 1∙555–3∙628, 
p<0∙0001; table 3). There were two treatment failures in 
each group. Of the 108 patients in the pharmacist-led care 
group who completed treatment, six (6%) did not attend 
for an SVR12 test (two patients died from unrelated 
causes); 12 (21%) of 58 patients in the conventional care 
group who completed treatment did not attend for an 
SVR12 test. Two (2%) of 108 patients in the pharmacist-
led treatment group and one (2%) of 58 patients in the 
conventional care group attended for an SVR12 test, but 
had an insufficient sample taken to complete the PCR 
test. Results from multiple logistic regression modelling 
exploring the patient and pharmacy characteristics that 
were associated with the primary and secondary outcomes 
were not significant (data not shown). For the sensitivity 
analysis, in which we assumed that patients who 
completed treatment had SVR12 (rather than treatment 
failure), a smaller effect size was shown because of the 
higher number of dropouts in the conventional care 
group. In this analysis, 106 (8%) of 1365 patients in the 
pharmacist-led care group had SVR12 compared with 
56 (4%) of 1353 patients in the conventional care group 
(OR 1∙95, 1∙397–2∙72, p<0·0001).
For the uptake of HCV testing, 245 (18%) of 
1365 patients on opioid substitution therapy in the 
pharmacist-led care group had a dry blood spot test, 
77 of whom tested antibody positive; 145 (11%) of 1353 in 
the conventional care group had a dry blood spot test, 
31 of whom tested antibody positive (OR 2∙292, 95% CI 
0∙968–5∙427; p=0∙06). 27 (11%) of the 245 participants 
in the pharmacist-led care group and 23 (16%) of the 
145 participants in the conventional care group were 
HCV PCR positive. The prevalence of HCV-positive 
tests from in-study testing across both groups was 50 
(13%) of 390. The most frequent reason for not 
proceeding with the treatment pathway in both groups 
was non-attendance (56 in the pharmacist-led care 
group, 23 in the conventional care group), with non-
eligible genotypes (two participants in the pharmacist-
Figure 2: Trial profile
HCV=hepatitis C virus. FIB-4=fibrosis 4.
61 initiated treatment
28 pharmacies randomised to the  conventional
 care pathway
28 pharmacies randomised to the  pharmacist-led 
 care pathway
58 completed treatment
3 lost to follow-up
1 pharmacy withdrew
1353 patients receiving opioid substitution therapy 
338 patients estimated to be HCV-positive
56 pharmacies assessed for eligibility and
 randomised 
1365 patients receiving opioid substitution therapy 
341 patients estimated to be HCV-positive
137 had HCV infection and consented to treatment
23 diagnosed by dry blood spot test
114 previously diagnosed with HCV
53 ineligible
49 did not attend for blood test
3 FIB-4 >3·25
1 personal reasons
23 did not attend
112 initiated treatment 
108 completed treatment
4 lost to follow-up
 3 personal choice
 1 missed 7 consecutive days of therapy
219 had HCV infection and consented to treatment
27 diagnosed by dry blood spot test
192 previously diagnosed with HCV
51 ineligible
43 did not attend for blood test
2 FIB-4 >3·25
2 not HCV genotype 1 or 3
1 pregnancy
3 personal reasons
56 did not attend
Conventional care (n=27) Pharmacist-led care (n=28)
Number of patients receiving opioid substitution therapy at start of 
study
20–29 4 (15%) 3 (11%)
30–39 6 (22%) 13 (46%)
40–49 7 (26%) 2 (7%)
50–59 6 (22%) 2 (7%)
≥60 4 (15%) 8 (29%)
SIMD quintile for pharmacy address
1 17 (63%) 14 (50%)
2 8 (30%) 7 (25%)
3 1 (4%) 4 (14%)
4 1 (4%) 1 (4%)
5 0 2 (7%)
SIMD=Scottish Index of Multiple Deprivation (1 being most deprived, 5 being 
least deprived). 
















led care group, zero in the conventional care group) and 
a FIB-4 score of more than 3·25 (two participants in the 
pharmacist-led care group, three in the conventional 
care group) being infrequent (figure 2). Other secondary 
outcomes analysed in the intention-to-treat population 
are shown in table 3.
In a per-protocol analysis of secondary outcomes, with 
denominators depending on stage of the cascade of care, 
219 (16%) of 1365 patients in the pharmacist-led pathway 
and 137 (10%) of 1353 in the conventional care pathway 
who were either newly diagnosed (27 in the pharmacist-led 
care group, 23 in the conventional care group) or previously 
diagnosed (192 in the pharmacist-led care group, 114 in the 
conventional care group) consented to receiving direct-
acting antiviral treatment after being approached by their 
pharmacists. 112 (51%) of 219 participants initiated 
treatment in the pharmacist-led care group compared with 
61 (44%) of 137 participants in the conventional care group. 
The median time between testing and commencement of 
treatment for the pharmacist-led care group was 46·5 days 
(IQR 16·1–76·9) and for the conventional care pathway 
was 71 days (17·5–124·5).
108 (49%) of 219 patients in the pharmacist-led care 
group and 58 (42%) of 137 in the conventional care group 
completed treatment. The proportion of patients who 
completed treatment among those who initiated treatment 
were similar between the two groups: 108 (96%) of 112 in 
the pharmacist-led care group and 58 (95%) of 61 in the 
conventional care group. The proportion of patients with a 
sustained virological response at 12 months (to assess 
potential reinfection) will be reported elsewhere; patients 
are still in follow-up for this outcome.
One participant in the pharmacist-led care group 
withdrew after assessment but before initiating therapy 
because of pregnancy. One patient in the pharmacist-led 
care group was discontinued from treatment because 
they missed 7 consecutive days of therapy. Six 
participants dropped out during treatment (three in the 
pharmacist-led care group, three in the conventional 
care group) through personal choice. During the study 
no adverse events, including serious adverse events, 
were identified.
In the post-hoc analysis, population cure rates more than 
doubled in the pharmacist-led care pathway compared 
with in the conventional care pathway (table 3). The results 
of our exploratory analysis using national surveillance 
data17 and within-study testing to describe the estimated 
numbers of participants who might have HCV infection at 
each stage in the care pathway are shown in figure 3.
Discussion
Our findings show that by making care more convenient 
for patients, the pharmacist-led care pathway led to 
more participants with SVR12 than did the conventional 
care pathway. We found that centralising the primary 
responsibility for HCV care in pharmacies led to more 
HCV testing and increased treatment uptake by patients 
who had previously tested HCV-positive, and 
maintained the high proportion of treatment success 
observed in the conventional care pathway.20 From the 
post-hoc notional population cure rates, treatment 
success rates more than doubled in this study. Also, 
because patient care was transferred out of hospital 
clinics and into pharmacies that the participants were 
already attending, the use of secondary care resources 
and the burden on patients are likely to have reduced. 
In a UK benchmark study, 11∙9% of the included 
population had evidence of ever receiving treatment 
and a smaller proportion (5·9%) were thought to have 






20–29 3 (5%) 3 (3%)
30–39 28 (46%) 63 (56%)
40–49 24 (39%) 43 (38%)
50–59 4 (6%) 3 (3%)
≥60 2 (3%)
Sex
Male 43 (70%) 70 (63%)
Female 18 (29%) 42 (37%)
FIB-4 score
<1·45 46 (75%) 68 (61%)
1·46–3·24 14 (23%) 42 (37%)
>3·25 0  2 (2%)*
HCV genotype
1 30 (49%) 37 (33%)
3 31 (51%) 75 (70%)
Proportions (%) have been rounded to the nearest whole number and might not 
total 100%. FIB-4=fibrosis 4. HCV=hepatitis C virus. *Patients continued to 
treatment despite meeting exclusion criteria after discussion between the 
pharmacy and multidisciplinary team. [A: footnote ok?]
Table 2: Baseline characteristics of participants who initiated treatment 





Odds ratio (95% CI) p value
SVR12 43 (3%) 98 (7%) 2·375 (1·555–3·628) <0·0001
Dry blood spot test 145 (11%) 245 (18%) 2·292 (0·968–5·427) 0·059
Consented 137 (10%) 219 (16%) 1·696 (1·350–2·131) <0·0001
Initiated treatment 61 (5%) 112 (8%) 1·889 (1·276–2·798) 0·0015
Completed treatment 58 (4%) 108 (8%) 1·928 (1·321–2·813) 0·0007
Diagnosed population 
cure rate*
137 (31%) 219 (45%) ·· ··
Notional population 
cure rate†
338 (13%) 341 (29%) ·· ··
SVR12=sustained virological response 12 weeks after completion of treatment. *The number of patients with SVR12 as 
a proportion of diagnosed patients. †The number of patients with SVR12 as a proportion of patients estimated to have 
infection.
















an HCV diagnosis attending an urban health network 
initiated treatment and 8% achieved SVR12.21 In the 
pharmacist-led care group in our study, the proportions 
were higher than in both these previous studies, with 
51% of patients with a diagnosis of HCV starting 
treatment and 45% achieving SVR12.
Using community pharmacies as the focal point of 
this intervention enabled a number of barriers to care 
that we identified in the literature and intervention 
development work to be overcome.22,23 Participants’ 
perceptions (recorded as part of our pilot work)22–25 were 
that the close proximity of the pharmacies and the 
trusting relationships formed between the pharmacists 
and people attending for opioid substitution services 
were important factors in encouraging HCV treatment 
participation, making service attendance easier (eg, no 
need to find money to travel),8,9 and removing the 
challenges of navigating the health system.26 These 
factors were expected to enhance uptake of HCV testing 
and treatment initiation, as was observed in this study; 
however, the increased uptake could also suggest that a 
less motivated and less selected group of patients 
initiated HCV treatment than normally would.27 It is 
noteworthy that the proportions of patients completing 
treatment compared with those initiating treatment was 
similar in both pathways, despite the higher treatment 
uptake in the pharmacist-led care group. We suggest 
that the proximity of pharmacies to where patients live, 
and the fact that the patients were already attending the 
pharmacy, might underlie the observed difference in 
treatment uptake in the intention-to-treat population 
and in the per-protocol populations.
The safety of direct-acting antiviral drugs means that 
many routinely measured analytes are no longer required 
(full blood count, liver function tests, viral load) and 
monitoring of safety outcomes can be simplified. The 
only outstanding issue is fibrosis estimation, which 
cannot be tested using capillary blood but can be 
managed with portable imaging methods such as 
elastography. The introduction of pangenotypic 
treatments of HCV reduces the complexity of clinical 
assessment, with an assessment for fibrosis being the 
main requirement, and further reduces the need for 
monitoring.28 However, it is important to ensure support 
from a specialist hepatitis team and a peripatetic 
phlebotomist when making this transition from 
conventional care to pharmacist-led care. The use of 
rapid RNA tests, currently being introduced and already 
being used in suitable environments, is expected to 
reduce the time taken to provide results to patients, 
increase the number of patients who remain engaged in 
the process, and reduce the time between diagnosis and 
treatment uptake.
The change from conventional care to pharmacist-led 
care was also expected to modify the behaviour of the 
pharmacist. Being assigned the primary responsibility for 
HCV testing and treatment was expected to prompt 
pharmacists to more actively participate in a novel clinical 
service. Community pharmacies received financial incen-
tivisation for participation in this service, as contractors 
within the NHS. The incentives provided might have 
motivated pharmacists to participate in the study and to 
complete follow-up with patients who were receiving 
antiviral treatment, although the exact mechan isms are 
impossible to disentangle from the effects of the 
intervention on participants. Participants self-selected to 
join the pharmacy pathway and it is unsurprising that 
many completed the course of treatment after electing to 
do so. The efficacy of direct-acting antiviral treatment is 
likely to deliver an SVR12 result if participants continued 
to attend for their opioid substitution therapy.
Pharmacists did not have access to skills and 
information sources that are available to hospital clinics, 
such as a phlebotomist and detailed medical histories 
Figure 3: Progress of participants to SVR12 through the cascade of care
Numbers of patients at each stage of the care pathway as a proportion of the estimated number of cases.17
Estimated as infected Diagnosed and agreed 
treatment



















































for the patients. This was not a barrier to care and no 
adverse events were observed. Close working with the 
specialist hepatitis team meant that any queries raised 
by the pharmacists could be efficiently dealt with 
through email or telephone; a visiting phlebotomist was 
able to meet with patients in their pharmacy. Although 
the full HCV treatment pathway could be delivered by 
pharmacies, ensuring support by a visiting phlebotomist 
and relationships with specialist teams seem to be 
important factors in making this pathway both safe and 
effective.
In a systematic review, we evaluated the performance of 
care pathways that use direct-acting antiviral drugs in a 
range of community and primary care settings, including 
studies based in opioid treatment services and integrated 
care arrangements (Extension for Community Health 
Outcomes, ECHO).29 We identified some evidence that 
HCV treatment provided in primary care and community 
environments could result in similar proportions of 
patients with SVR12 to specialist care, and increase the 
numbers of people who could access care. From the 
17 studies included, just two were randomised controlled 
trials, one of which was the feasibility study24 we did in 
preparation for this study. The feasibility study also showed 
an increase in testing uptake and increased retention in 
care in pharmacist-led care compared with conventional 
care. The second randomised controlled trial30 showed 
increased treatment uptake and proportions of patients 
with SVR12 in primary care sites compared with standard 
of care, and provided evidence of the applicability of 
moving care to primary care and community settings in an 
international context.
Our study has shown greater effectiveness of a 
pharmacist-led treatment pathway, which included close 
collaboration between specialist clinics and pharmacies 
and directly observed treatment of HCV at the pharmacies, 
compared with a gold standard comparator (the conven-
tional care pathway).20 The use of pharmacists to deliver 
care to different patient groups is expanding rapidly 
because of the availability of safer medicines, the need to 
access disadvantaged communities, and the widening of 
the multidisciplinary team. Cost-effectiveness of the 
pharmacist-led care pathway is being evaluated as part of 
our programme of ongoing work. 
We believe that our comparator care pathway was 
innovative, being community-facing, multidisciplinary, 
and involving nurse prescribing. The Tayside region of 
Scotland has been a test bed for sequential development 
of integrated services for HCV care over the past 
two decades,31 moving from standard secondary care-
based hospital outpatients, onto nurse-supported 
treatment services, to a HCV managed care network, 
and finally to a development in the managed care 
network model, which included a widespread dry blood 
spot testing programme in drug services and 
development in outreach services across the region, 
including providing treatment within drug services and 
prisons.20 That we nevertheless observed such an 
increase in treatment uptake and effectiveness in the 
pharmacist-led care group provides strong additional 
support for the WHO guidelines on care and treatment 
of individuals diagnosed with chronic HCV infection (ie, 
the importance of simplified service delivery models, 
integration with other services, decentralised services 
supported by task-sharing, and community engagement 
to address stigma and increase reach).6 Increasing access 
to care by lowering barriers to treatment will be essential 
to achieve the goals outlined in the WHO guidelines. 
This study shows a way that this increase in access to 
care can be accomplished.
This cluster-randomised controlled study had several 
strengths: the intervention was developed iteratively and 
pragmatically using Medical Research Council guidance 
for developing and evaluating complex interventions;32 
pilot work was done using focus groups, examination of 
patient preferences, testing of elements of the pathway, 
and implementation of a feasibility trial to aid the design 
of the pharmacist-led pathway;22–25 and the intervention 
was based on a pilot study, was feasible, and was well 
powered.
The main weaknesses of our study are, first, that we 
could only collect participant data after dry blood spot 
testing from participants who consented to treatment, 
which did not represent true baseline data (which would 
have required us to collect data on the full randomised 
sample of all patients prescribed opioid substitution 
therapy in the participating pharmacies). Second, the 
number of study participants who did not present for a 
confirmatory SVR12 blood test was slightly higher in the 
conventional care group than in the pharmacist-led care 
group, which could inflate the treatment effect. However, 
a sensitivity analysis assuming that all participants who 
completed treatment had SVR12 confirmed the effect 
shown in the pharmacist-led care group. Finally, the 
participating pharmacies might have been a selection of 
those already interested in taking on this additional 
HCV test-and-treat responsibility, hence, the success of 
the pathway should be closely monitored when it is 
implemented in routine health services.
The pharmacist-led care pathway is a safe and effective 
approach to improving the reach and impact of HCV 
treatment. The use of direct-acting antiviral drugs means 
that monitoring and management of patients are 
straightforward: risk of cirrhosis can be assessed using 
routine blood tests, and ongoing monitoring of 
participants can be done during routine attendance for 
opioid substitution therapy. This study shows that 
conven iently organising the entire HCV treatment 
pathway in community pharmacies—compared with a 
pathway comprising state-of-the-art HCV care by 
pharmacies in collaboration with secondary care 
treatment centres—can double HCV testing and 
treatment consent rates, and retain excellent treatment 
















complementary strategy for achieving the WHO target of 
eliminating HCV.
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